News >

Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Nears EU Approval in Nonsquamous NSCLC

Gina Columbus @ginacolumbusonc
Published: Monday, Jul 29, 2019

Sandra Horning, MD, chief medical officer and head of Global Product Development, Roche

Sandra Horning, MD

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion to the triplet regimen of atezolizumab (Tecentriq), carboplatin, and nab-paclitaxel (Abraxane) for the first-line treatment of patients with advanced, nonsquamous non–small cell lung cancer (NSCLC) who do not have EGFR or ALK molecular aberrations.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x